Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they will ensure that immunocompromised patients will have to wait no more than nine months from approval to get the prophylactic antibodies Evusheld.

The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is based on independent clinical advice by the multi-agency RAPID C-19 and a United Kingdom national expert policy working group, which reflects the epidemiological context and pandemic response and recovery policies. However, we have referred Evusheld to the National Institute for Health and Care Excellence (NICE) for evaluation, which is due in April 2023. Following NICE’s review, if a positive recommendation is made, National Health Service commissioners will be obliged to provide treatments within 90 days of publication.